Financials

v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 7,129 $ 17,116
Prepaid expenses and other current assets 535 827
Total Current Assets 7,664 17,943
Property and equipment, net 731 872
Deposits and other assets 23 23
Total Assets 8,418 18,838
Current Liabilities:    
Accounts payable 1,217 2,020
Accrued expenses 1,000 1,526
Warrant liabilities 645 4,083
Accrued employee benefits 1,362 2,074
Deferred rent 95 90
Total Current Liabilities 4,319 9,793
Long term deferred rent 353 402
Total Liabilities 4,672 10,195
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized,120,000 issued and outstanding 12,173 12,053
Stockholders' Deficit:    
Common stock,  $0.001 par value; 350,000,000 shares authorized,130,380,517 issued and 130,299,305 outstanding and 117,254,196 issued and 117,172,714 outstanding 130 129
Additional paid-in capital 194,186 192,545
Accumulated deficit (200,803) (194,170)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit (6,487) (1,496)
Non-controlling interest (1,940) (1,914)
Total Stockholders' Deficit (8,427) (3,410)
Total Liabilities and Stockholders' Deficit $ 8,418 $ 18,838

Source

v3.10.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Operating Costs and Expenses:        
General and administrative $ 1,431 $ 1,644 $ 3,051 $ 3,734
Research and development 3,572 4,831 6,942 10,891
Total Operating Costs and Expenses 5,003 6,475 9,993 14,625
Loss from Operations (5,003) (6,475) (9,993) (14,625)
Other Income:        
Change in fair value of warrant liability 783 2,159 3,438 7,249
Interest income 6 1 15 3
Total Other Income 789 2,160 3,453 7,252
Net Loss (4,214) (4,315) (6,540) (7,373)
Net Loss Attributable to Non-controlling Interest (17) (60) (26) (272)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (4,197) (4,255) (6,514) (7,101)
Series A Preferred Stock Dividends (61) (120) 0
Net Loss Attributable to Common Stock Holders $ (4,258) $ (4,255) $ (6,634) $ (7,101)
Net Loss Per Share - Basic and Dilutive $ (0.03) $ (0.03) $ (0.05) $ (0.06)
Weighted average number of shares outstanding during the period - Basic and Dilutive 128,918,408 123,005,220 128,743,616 120,241,593

Source

v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash Flows From Operating Activities:    
Net Loss $ (6,540) $ (7,373)
Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation    
Stock-based compensation 1,233 2,006
Warrant issued to consultant 9 0
Change in fair value of warrant liabilities (3,438) (7,249)
Depreciation and amortization 141 116
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 292 975
Accounts payable (803) (271)
Accrued expenses (526) (877)
Accrued employee benefits (711) 896
Deferred rent (44) 29
Net Cash Used In Operating Activities (10,387) (11,748)
Cash Flows From Investing Activities:    
Purchases of property and equipment 0 (11)
Net Cash Used In Investing Activities 0 (11)
Cash Flows From Financing Activities:    
Proceeds from issuance of common stock for stock option exercises 0 166
Proceeds from "at the market" stock issuance 400 5,914
Net Cash Provided By Financing Activities 400 6,080
Net decrease in cash (9,987) (5,679)
Cash at beginning of period 17,116 19,055
Cash at end of period $ 7,129 $ 13,376

Source